BridgeBio Pharma (BBIO) Cash from Financing Activities (2018 - 2026)

BridgeBio Pharma has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $549.9 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $549.9 million, up 811.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $848.9 million (up 60.39% YoY), and the FY2025 annual result was $359.3 million, down 52.0% from the prior year.
• Cash from Financing Activities came in at $549.9 million for Q1 2026 at BridgeBio Pharma, up from -$2.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $549.9 million in Q1 2026 to a low of -$20.8 million in Q2 2022.
• The 5-year median for Cash from Financing Activities is $1.4 million (2022), against an average of $123.3 million.
• Across the five-year window, Cash from Financing Activities tumbled 1395.04% in 2022 and surged 94005.62% in 2023, its largest moves.
• BridgeBio Pharma's Cash from Financing Activities stood at $6.4 million in 2022, then tumbled by 170.93% to -$4.5 million in 2023, then surged by 10578.24% to $473.9 million in 2024, then slumped by 100.46% to -$2.2 million in 2025, then soared by 25301.28% to $549.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $549.9 million (Q1 2026), -$2.2 million (Q4 2025), and -$894000.0 (Q3 2025), per Business Quant data.